# Moderna Stock to Lead Healthcare in 2026

> Moderna's cancer vaccine breakthrough could make it the top healthcare stock by 2026 despite Wall Street skepticism.
- Title: Moderna Stock to Lead Healthcare in 2026 · The Motley Fool
- Summary: Moderna's cancer vaccine breakthrough could make it the top healthcare stock by 2026 despite Wall Street skepticism. Moderna's personalized cancer vaccine…
- Keywords: moderna, cancer vaccine, intismeran autogene, merck, keytruda, mflusiva, healthcare stocks, 2026, stock market, finance, money, Stock
- Source: The Motley Fool — https://fool.com/investing/2026/10/21/not-lilly-not-johnson-johnson-this-stock-will-be-t
- Author: Prosper Junior Bakiny
- Published: 2026-10-21T14:00:00+00:00
- Read time: 1 min
- Topics: moderna, cancer vaccine, intismeran autogene, merck, keytruda, mflusiva, healthcare stocks, 2026, stock market, finance, money
## Moderna's 2026 Healthcare Potential
Moderna is expected to be the biggest healthcare winner among large-cap stocks in 2026.
## Moderna's Recent Stock Performance
Moderna stock has dropped 17.57% to $202.63 after a 600% surge in 2026.
## Cancer Vaccine Breakthrough
Moderna's investigational personalized cancer vaccine achieved a statistically significant improvement in recurrence-free survival.

> intismeran autogene achieved a statistically significant improvement in recurrence-free survival when combined with Merck's Keytruda
## mFLUSIVA Influenza Vaccine
Moderna received approval for mFLUSIVA, an influenza vaccine for people aged 50 and older.
## Wall Street Skepticism
Wall Street expects Moderna's stock to drop 45% from current levels by 2032.

> Wall Street's average price target is $123.61, implying a 45% downside from current levels
## Financial Projections
Moderna needs $6.34 billion in net income by 2032 to meet Wall Street's expectations.
## Key takeaway

Moderna's personalized cancer vaccine shows promise but Wall Street expects a 45% price drop by 2032.